China's Ascletis Pharma H1 net loss widens on higher R&D costs

Ascletis Pharma

31/08/2026 14:31

Overview
China biopharma developer's interim net loss widened 263% yr/yr to RMB319.7 mln
Total income for the period fell 49% yr/yr
R&D expenses surged 133% yr/yr due to expanded metabolic disease pipeline investment

Outlook
Company did not provide specific financial guidance for the current or future periods in the press release

Result Drivers
R&D EXPENSES - Co said net loss widened mainly due to a 133% yr/yr surge in R&D costs from expanded metabolic disease pipeline investment
INCOME DECLINE - Co reported total income fell 49% yr/yr, contributing to wider losses

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Net Loss Attributable
 
RMB 319.67 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Ascletis Pharma Inc. is HK$15.71, about 55.5% above its August 28 closing price of HK$10.10

Reuters Recommended Reads
Aug 31 - Israel's BioLineRx Q2 net loss widens on higher R&D expenses
Aug 31 - China's CANbridge Pharmaceuticals H1 revenue rises on Hunterase and Livmarli strength
Aug 28 - BioNTech halts mRNA colorectal cancer vaccine trial after safety review

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)